-
E. coli Uracil-DNA Glycosylase (UDG) Guide
2026-09-15
E. coli Uracil-DNA Glycosylase (UDG), SKU K1107, removes uracil residues from single- and double-stranded DNA to support PCR product contamination elimination and DNA repair enzyme workflows. It is intended for research use with DNA substrates, not RNA, oligonucleotides shorter than six bases, or diagnostic and medical applications.
-
Angiotensin 1/2 (1-6) Research Workflows
2026-09-15
Use the Asp-Arg-Val-Tyr-Ile-His hexapeptide to build controlled assays for renin-angiotensin system research, vascular signaling, renal physiology, and receptor-binding studies. A practical workflow combines careful peptide handling with concentration-response controls and a newer spike–AXL assay application reported in 2025.
-
Adefovir Dipivoxil in Chronic Hepatitis B
2026-09-14
Hadziyannis and Papatheodoridis synthesized preclinical and clinical evidence showing that adefovir dipivoxil suppresses both HBeAg-positive and HBeAg-negative chronic hepatitis B, including lamivudine-resistant infection. The review’s central contribution is its interpretation of Adefovir as a comparatively durable nucleotide analog antiviral, linking selective HBV polymerase inhibition with long-term clinical utility and resistance management.
-
Novel PDK4 Inhibitors for Metabolic Disease
2026-09-14
The 2019 Journal of Medicinal Chemistry study identified compound 8c as an allosteric pyruvate dehydrogenase kinase 4 inhibitor with 84 nM in vitro potency and favorable early drug-development properties. Its activity in obese-mouse glucose tolerance and passive cutaneous anaphylaxis models supports PDK4 as a pharmacological target, while docking and cellular studies define a broader hypothesis for metabolic, inflammatory, and cancer research.
-
Z-IETD-FMK: Apoptosis–Pyroptosis Assay Logic
2026-09-13
Z-IETD-FMK is a mechanistic probe for separating caspase-8-dependent apoptosis from caspase-1-driven pyroptosis. This guide integrates its pharmacology with the HOXC8–caspase-1 lung cancer study to improve cell-death assay design and interpretation.
-
SCH772984 HCl: ERK1/2 Beyond MAPK
2026-09-12
A translational framework for using SCH772984 HCl to dissect ERK1/2 signaling, treatment resistance, and the emerging connection between MAPK activity, TERT regulation, and DNA repair biology.
-
Trifluoperazine 2HCl: Assay Workflows
2026-09-11
Trifluoperazine 2HCl supports tightly controlled dopamine D2 receptor experiments while also enabling exploratory studies of macrophage ROS, autophagy, and cancer-cell phenotypes. This guide connects practical stock preparation, dose-response design, orthogonal readouts, and troubleshooting with lessons from a distinct PDK4 inhibitor discovery program.
-
EdU Cell Proliferation Kit for S-Phase Assays
2026-09-11
The EdU Cell Proliferation Kit provides a non-radioactive 5-ethynyl-2'-deoxyuridine proliferation assay for detecting DNA synthesis during S phase. Its CuAAC biotin-labeling and HRP-streptavidin/TMB workflow supports cell proliferation measurement, genotoxicity testing assay development, and pharmacodynamic drug evaluation.
-
PAD4-IN-2 TFA: From Targeting to Assay Design
2026-09-10
PAD4-IN-2 TFA, also known as Compound 5i TFA, connects tumor-directed uptake with PAD4-H3cit-NET biology. This guide explains how to interpret its enzymatic, cellular, immune, and in vivo data without confusing pathway inhibition with direct cytotoxicity.
-
SAG and Developmental Biology: A Dose-to-Design Guide
2026-09-10
SAG is more than a Hedgehog pathway activator: it is a causal probe for separating pathway amplitude, developmental timing, and tissue-specific outcomes. This guide interprets recent tongue-development findings and translates them into better assay design, controls, and preclinical decision-making.
-
EPZ5676: DOT1L Inhibitor Workflow Guide
2026-09-09
EPZ5676 connects SAM-competitive DOT1L biochemistry with H3K79 methylation inhibition, MLL-rearranged leukemia studies, and emerging multiple myeloma assays. This workflow guide emphasizes concentration design, orthogonal validation, combination testing with lenalidomide, and practical troubleshooting.
-
PTGER4–HDAC Signaling in Rectal Epithelial Cells
2026-09-09
The reference study identifies a mechanistic link between mesenchymal stromal cell-derived PGE2, epithelial PTGER4 signaling, class IIa HDAC phosphorylation, and SPINK4 mRNA regulation in rectal organoids. Its integrated organoid, co-culture, imaging, transcript, and protein analyses provide a framework for studying epithelial repair pathways while highlighting the importance of preserving phosphorylation states during biochemical workflows.
-
BMS 309403: A Practical FABP4 Inhibitor Workflow
2026-09-08
BMS 309403 provides a selective, mechanism-focused way to interrogate FABP4 in macrophage lipid handling, foam cell formation, and inflammatory signaling. This workflow connects dose-response cell assays with atherosclerosis and metabolic disease models while emphasizing solubility, controls, and interpretation.
-
Axitinib (AG 013736): From Potency to Translation
2026-09-08
A mechanistic and strategic guide to using Axitinib (AG 013736) in VEGF pathway studies, angiogenesis inhibition assays, and tumor xenograft research—while separating pathway control from broader drug-response effects.
-
Neuritin, ER Stress, and NF-κB After SAH
2026-09-07
The reference study maps three endoplasmic-reticulum-stress inflammatory branches to neuroinflammation and neuronal apoptosis during early brain injury after subarachnoid hemorrhage. Its main contribution is showing that neuritin overexpression suppresses convergent NF-κB signaling across these branches, offering a mechanistic framework for studying neuroprotection without equating preclinical pathway modulation with clinical efficacy.